Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 15, 2026

Sunset Pier 94 Studios Announces Inaugural Lease with Paramount Television Studios for Dexter®: Resurrection Ahead of Opening

View original at finance.yahoo.com
Sunset Pier 94 Studios Announces Inaugural Lease with Paramount Television Studios for Dexter®: Resurrection Ahead of Opening Paramount Television Studios Has Leased 70,000 Square Feet for Filming Season Two of the Hit Showtime® Original Series NEW YORK, January 15, 2026--(BUSINESS WIRE)--Today, Vornado Realty Trust (N…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Paramount Television Studios is thrilled to bring the second season of Dexter: Resurrection to Sunset Pier 94 Studios and its state-of-the-art facilities and sound stages

    80% confidence

  • Sunset Pier 94 Studios is expected to create 400 permanent jobs and contribute $6.4 billion to the local economy over the next 30 years

    80% confidence

  • Sunset Studios' success in attracting and retaining top-tier productions across multiple seasons speaks to the caliber of studios and services

    80% confidence

  • Last season saw Dexter move to New York City and now the production will follow suit, gaining greater access to the region's incredible creative talent

    80% confidence

  • Robust pre-leasing interest in Sunset Pier 94 Studios underscores the project's unmatched quality and prime location with nothing else like it in the market

    80% confidence

  • Season one of Dexter: Resurrection was filmed in New York, generating significant economic impact in neighborhoods through jobs and small business spending

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com